As­traZeneca, Gilead de­tail TROP2 ADC da­ta in lung can­cer as they search for new ways for­ward

As­traZeneca is fo­cus­ing on a sub­group of lung can­cer pa­tients as it seeks a path to ap­proval for its TROP2-di­rect­ed an­ti­body-drug con­ju­gate, which ear­li­er this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER